BeOne Medicines (ONC) Income from Continuing Operations: 2015-2025
Historic Income from Continuing Operations for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $124.8 million.
- BeOne Medicines' Income from Continuing Operations rose 202.88% to $124.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.5 million, marking a year-over-year increase of 107.97%. This contributed to the annual value of -$644.8 million for FY2024, which is 26.87% up from last year.
- Per BeOne Medicines' latest filing, its Income from Continuing Operations stood at $124.8 million for Q3 2025, which was up 32.36% from $94.3 million recorded in Q2 2025.
- In the past 5 years, BeOne Medicines' Income from Continuing Operations ranged from a high of $215.4 million in Q3 2023 and a low of -$590.7 million during Q4 2021.
- Over the past 3 years, BeOne Medicines' median Income from Continuing Operations value was -$121.3 million (recorded in 2024), while the average stood at -$118.7 million.
- As far as peak fluctuations go, BeOne Medicines' Income from Continuing Operations crashed by 754.48% in 2022, and later spiked by 202.88% in 2025.
- Over the past 5 years, BeOne Medicines' Income from Continuing Operations (Quarterly) stood at -$590.7 million in 2021, then increased by 24.61% to -$445.3 million in 2022, then grew by 17.47% to -$367.6 million in 2023, then skyrocketed by 58.68% to -$151.9 million in 2024, then surged by 202.88% to $124.8 million in 2025.
- Its last three reported values are $124.8 million in Q3 2025, $94.3 million for Q2 2025, and $1.3 million during Q1 2025.